Table 4.
DHEA-S and E1-S transporters and estrogen biosynthetic enzymes in ovarian cancer.
| Gene | Level | Cell line | Tumor tissue | ||
|---|---|---|---|---|---|
| Regulation | Reference | Regulation | Reference | ||
| OATP1B1 | mRNA | ↑ Serous epithelial adenocarcinoma/control tissue | Svoboda et al., 2011 | ||
| OATP1B3 | mRNA | IGROV1, OVCAR-3, OVCAR-4, OVCAR5, OVCAR-8, SK-OV-3, Expressed | Lancaster et al., 2013 | Cancer/control tissue ↑ | Lancaster et al., 2013 |
| OVCAR-3, SK-OV-3, Expressed, ↑ OVCAR-3/SK-OV-3 | Svoboda et al., 2011 | ↑ Serous epithelial adenocarcinoma/control tissue | Svoboda et al., 2011 | ||
| OATP2B1 | mRNA | ↑ Serous epithelial adenocarcinoma/control tissue | Svoboda et al., 2011 | ||
| OATP4A1 | mRNA | ↑YDOV-151 (mucinous adenocarcinoma), SK-OV-3/HOSE | Cho et al., 2009 | ≈ Serous epithelial adenocarcinoma/control tissue | Svoboda et al., 2011 |
| ↑YDOV-139 (serous carcinoma) | Chay et al., 2010 | ||||
| OATP4C1 | mRNA | ≈ Serous epithelial adenocarcinoma/control tissue | Svoboda et al., 2011 | ||
| ABCC1 | mRNA | Expressed in serous, mucinous, clear cell, endometrioid, undifferentiated cancer | Reviewed by (Ween et al., 2015) | ||
| Protein | Positive IHC in 22–68% of ovarian cancers | Reviewed by (Ween et al., 2015) | |||
| ABCC4 | Protein | 127 OC patients; association with shorter progress free survival | Bagnoli et al., 2013 | ||
| ABCG2 | Protein | Induced in PA-1 OC cell line transfected with ESR1 | Ee et al., 2004 | Expressed in OC, a marker of of OC stem cells | Zhang et al., 2008 |
| ↑ resistant OC (carboplatin + paclitaxel) | Ween et al., 2015 | ||||
| STS | mRNA | ≈ EOC (9–10)/OSE (17) | Ren et al., 2015 | ||
| Protein | 70% clear cell (32/45); 33% serous (6/18); and 50% mucinous adenocarcinoma (4/8) | Okuda et al., 2001 | |||
| Expressed EOC and OSE | Ren et al., 2015 | ||||
| 17% Cancer low/moderate, Normal ovary low (stromal cells) | Human Protein Atlas | ||||
| Activity E1-S | ↑ SKOV-3, PEO-1 vs. OSE | Ren et al., 2015 | ↑ STS ↓ progression-free survival, epithelial OC (48), serous OC (34) | Chura et al., 2009a,b | |
| OC-117 | Milewich and Porter, 1987 | ||||
| SULT1E1 | mRNA | ↓ EOC (9–10)/OSE (17) | Ren et al., 2015 | ||
| Protein | Expressed EOC and OSE | Ren et al., 2015 | 17% Cancer moderate/normal ND | Human Protein Atlas | |
| Expressed | Ren et al., 2015 | ||||
| Activity E1 | ↑ SKOV-3, PEO-1 vs. OSE | Ren et al., 2015 | |||
| HSD17B1 | Activity E1 → E2 | ↑ SKOV-3, PEO-1 vs. OSE | Ren et al., 2015 | ||
| HSD17B2 | mRNA | ↓ EOC (9–10)/OSE (17) | Ren et al., 2015 | ||
| Protein | Expressed | Ren et al., 2015 | |||
| Activity E2 | Epithelial OC (48), serous OC (34) | Chura et al., 2009b | |||
| AKR1C3 | mRNA | ↓ EOC (9–10)/OSE (17) | Ren et al., 2015 | ||
| Protein | Expressed | Ren et al., 2015 | |||
| Activity T | Epithelial OC (48), serous OC (34) | Chura et al., 2009b | |||
| HSD3B1/2 | Activity DHEA | Epithelial OC (48), serous OC (34) | Chura et al., 2009b | ||
EOC, epithelial ovarian carcinoma; OSE, ovarian surface epithelia; OCCA, ovarian clear-cell adenocarcinoma, IGROV1, OVCAR-3, OVCAR-4, OVCAR5, OVCAR-8, SK-OV-3, AC-258, OC-117, PEO-1; ovarian cancer cell lines.